Biotech Conclude Asset Transfer of Cancer Vaccine Product
The EP-2101 cancer vaccine candidate used in the phase 2 trial includes nine CTL epitopes from four tumor associated antigens (TAA). Two are proprietary native epitopes and seven are modified, or analog, epitopes.
Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes, which enhance the potency of the T cell response.
The open label, non-randomized phase 2 was designed to assess overall survival at one year and vaccine safety, with vaccine immunogenicity as a secondary endpoint, in HLA-A2 positive patients with stage IIIb, IV or recurrent non-small cell lung cancer (NSCLC).
According to Biotech, 68 patients were enrolled in the trial (sixty-three treated). Patients were also required to have tumor volume less than 125 cm2 with no limits on prior chemotherapy.
One-year survival in patients treated with EP-2101 was 60 percent, compared to 49 percent in a group of patients who were HLA-A2 negative but otherwise comparable (concurrent controls).
Median survival for patients treated with EP-2101 was 583 days compared to 361 days for patients in the control group. Ninety-one percent of patients treated with EP-2101, who were tested for immune response, had a measurable response to at least one of the epitopes included in the vaccine with 64 percent responding to at least three of the epitopes.
Emile Loria, managing director of Biotech Synergy, said: â€œWe have been able to reactivate very quickly the core competences needed to bring this cancer vaccine opportunity developed while at Epimmune. We are now ready to discuss this opportunity with various potential partners in Europe and US.â€
Will the acquisition enhance Biotechâ€™s portfolio?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.